Interest in quantitative imaging of Y-90 is growing because transarterial radioembolization (RE) with Y-90 loaded microspheres is a promising and minimally invasive treatment that is FDA approved for unresectable primary and metastatic liver tumors. These cancers are a leading cause of cancer mortality and morbidity. Radioembolization is a therapy that irradiates liver tumors with radioactive microspheres administered through a microcatheter placed in the hepatic arterial vasculature. Radioembolization is based on the principle that healthy liver and tumor are mainly vascularized by the portal vein and the hepatic artery respectively. As a result, radioactive microspheres are preferentially located in the lesions after they are administered via the hepatic artery.
This publication contains anonymized time integrated activity maps for two patients. SPECT/CT scans were taken at 4 different time points in the week following a therapeutic dose of Lu-177 DOTATATE and combined into a single activity map for each patient. All images are in DICOM format.
This publication contains anonymized DICOM structure files that were outlined on SPECT/CT scans for two patients. Organ contours include the liver, right and left kidneys, and spleen when present. Two to four lesions were outlined for each patient.
This publication contains the anonymized SPECT/CT scans of two patients. Patient scans were taken at 4 different time points in the week following a therapeutic dose of Lu-177 DOTATATE. Each of the scans contains 5 subfolders, 3 of which contain SPECT projection data used for reconstructing SPECT images, and 2 contain the linear attenuation coefficient maps for the CT scans that correspond to each patients SPECT projections. All images are in DICOM format.
This publication contains anonymized SPECT/CT scans of two patients. Patient scans were taken at 4 different time points in the week following a therapeutic dose of Lu-177 DOTATATE. Both the SPECT and the co-registered CT are provided. All images are in DICOM format.